Biologic Drug Product Outsourcing Drivers by Company Size

In Q3 2021, ISR surveyed 136 sponsors who outsource biologic drug product manufacturing to learn more about their primary reason for outsourcing. The data show that sponsors from large pharma tend to use CMOs to augment internal manufacturing capacity (71%) while sponsors from non-large pharma use CMOs for all manufacturing needs (66%). To learn more, follow the link to the Biologic Drug Product CDMO Benchmarking report preview.